{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T06:42:09Z","timestamp":1795156929095,"version":"4.10.3"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Oncogenic signaling through the MAPK\/ERK pathway drives tumor progression in many cancers. Although targeted MAPK\/ERK pathway inhibitors improve survival in selected patients, most tumors are resistant. New drugs could be identified in small-animal models that, unlike in vitro models, can address oral uptake, compound bioavailability, and toxicity. This requires pharmacologic conformity between human and model MAPK\/ERK pathways and available phenotypic assays. In this study, we test if the conserved MAPK\/ERK pathway in Caenorhabditis elegans could serve as a model for pharmacological inhibition and develop in vivo pipelines for high-throughput compound screens. Using fluorescence-based image analysis of vulva development as a readout for MAPK\/ERK activity, we obtained excellent assay Z-scores for the MEK inhibitors trametinib (Z = 0.95), mirdametinib (Z = 0.93), and AZD8330 (Z = 0.87), as well as the ERK inhibitor temuterkib (Z = 0.86). The throughput was 800 wells per hour, with an average seed density of 25.5 animals per well. Readouts included drug efficacy, toxicity, and pathway specificity, which was tested against pathway activating upstream (lin-15)- and downstream (lin-1) mutants. To validate the model in a high-throughput setting, we screened a blinded library of 433 anticancer compounds and identified four MEK inhibitors among seven positive hits. Our results highlight a high degree of pharmacological conformity between C. elegans and human MAPK\/ERK pathways, and the presented high-throughput pipeline may discover and characterize novel inhibitors in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Many tumors depend on MAPK\/ERK signaling to sustain growth, avoid cell death, and metastasize. We show that specific and clinically relevant MAPK\/ERK signaling inhibitors can be discovered in vivo with a high-throughput screening pipeline in small animals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0221","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T09:53:32Z","timestamp":1725011612000},"page":"2454-2462","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Drug Discovery Pipeline for MAPK\/ERK Pathway Inhibitors in\n                    <i>Caenorhabditis elegans<\/i>"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-7316","authenticated-orcid":false,"given":"Szymon","family":"Gorgo\u0144","sequence":"first","affiliation":[{"name":"Department of Diagnostics and Intervention, Surgery, Ume\u00e5 University, Ume\u00e5, Sweden. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5824-6263","authenticated-orcid":false,"given":"Ola","family":"Billing","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Intervention, Surgery, Ume\u00e5 University, Ume\u00e5, Sweden. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8853-1863","authenticated-orcid":false,"given":"Anna U.","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Chemical Biology Consortium Sweden, Ume\u00e5 University, Ume\u00e5, Sweden. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1732-168X","authenticated-orcid":false,"given":"Oskar","family":"Hemmingsson","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Intervention, Surgery, Ume\u00e5 University, Ume\u00e5, Sweden. 1"},{"name":"Wallenberg Centre for Molecular Medicine, Ume\u00e5 University, Ume\u00e5, Sweden. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"2025040317224549700_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"2025040317224549700_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","article-title":"The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy","volume":"13","author":"Yuan","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2025040317224549700_bib3","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"2025040317224549700_bib4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"2025040317224549700_bib5","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jid.2021.10.007","article-title":"Vemurafenib drives epithelial-to-mesenchymal transition gene expression in BRAF inhibitor\u2012resistant BRAFV600E\/NRASQ61K melanoma enhancing tumor growth and metastasis in a bioluminescent murine model","volume":"142","author":"Jandova","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2025040317224549700_bib6","doi-asserted-by":"crossref","first-page":"102137","DOI":"10.1016\/j.ctrv.2020.102137","article-title":"MEK inhibitor resistance mechanisms and recent developments in combination trials","volume":"92","author":"Kun","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2025040317224549700_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025040317224549700_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2019.04.027","article-title":"Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: a randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219","volume":"133","author":"Melosky","year":"2019","journal-title":"Lung Cancer"},{"key":"2025040317224549700_bib9","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2025040317224549700_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/ph13080164","article-title":"Phenotypic screening in C. elegans as a tool for the discovery of new geroprotective drugs","volume":"13","author":"Bulterijs","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025040317224549700_bib11","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2147\/DDDT.S129447","article-title":"Cell and small animal models for phenotypic drug discovery","volume":"11","author":"Szabo","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"2025040317224549700_bib12","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/biot.200600176","article-title":"Caenorhabditis elegans: a versatile platform for drug discovery","volume":"1","author":"Artal-Sanz","year":"2006","journal-title":"Biotechnol J"},{"key":"2025040317224549700_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/adt.2018.908","article-title":"High-content and high-throughput in vivo drug screening platforms using microfluidics","volume":"17","author":"Ben-Yakar","year":"2019","journal-title":"Assay Drug Dev Technol"},{"key":"2025040317224549700_bib14","doi-asserted-by":"crossref","first-page":"e00721","DOI":"10.1002\/prp2.721","article-title":"Drug discovery: insights from the invertebrate Caenorhabditis elegans","volume":"9","author":"Giunti","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"2025040317224549700_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ccr.2005.03.024","article-title":"Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors","volume":"7","author":"Lackner","year":"2005","journal-title":"Cancer Cell"},{"key":"2025040317224549700_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4062\/biomolther.2014.084","article-title":"Caenorhabditis elegans: a model system for anti-cancer drug discovery and therapeutic target identification","volume":"22","author":"Kobet","year":"2014","journal-title":"Biomol Ther (Seoul)"},{"key":"2025040317224549700_bib17","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2019.08.003","article-title":"Host-microbe-drug-nutrient screen identifies bacterial effectors of metformin therapy","volume":"178","author":"Pryor","year":"2019","journal-title":"Cell"},{"key":"2025040317224549700_bib18","doi-asserted-by":"crossref","first-page":"10321","DOI":"10.1158\/0008-5472.CAN-10-1548","article-title":"ASNA-1 activity modulates sensitivity to cisplatin","volume":"70","author":"Hemmingsson","year":"2010","journal-title":"Cancer Res"},{"key":"2025040317224549700_bib19","doi-asserted-by":"crossref","first-page":"8678","DOI":"10.1038\/s41598-021-88085-y","article-title":"Alternative redox forms of ASNA-1 separate insulin signaling from tail-anchored protein targeting and cisplatin resistance in C. elegans","volume":"11","author":"Raj","year":"2021","journal-title":"Sci Rep"},{"key":"2025040317224549700_bib20","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1038\/s41388-021-01808-3","article-title":"LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance","volume":"40","author":"Billing","year":"2021","journal-title":"Oncogene"},{"key":"2025040317224549700_bib21","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1073\/pnas.1615651114","article-title":"In vivo severity ranking of Ras pathway mutations associated with developmental disorders","volume":"114","author":"Jindal","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025040317224549700_bib22","first-page":"546","article-title":"Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish","volume":"5","author":"Anastasaki","year":"2012","journal-title":"Dis Model Mech"},{"key":"2025040317224549700_bib23","doi-asserted-by":"crossref","first-page":"10434","DOI":"10.1158\/0008-5472.CAN-06-2182","article-title":"A conserved RAS\/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans","volume":"66","author":"Weidhaas","year":"2006","journal-title":"Cancer Res"},{"key":"2025040317224549700_bib24","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1093\/nar\/25.17.3389","article-title":"Gapped BLAST and PSI-BLAST: a new generation of protein database search programs","volume":"25","author":"Altschul","year":"1997","journal-title":"Nucleic Acids Res"},{"key":"2025040317224549700_bib25","doi-asserted-by":"crossref","first-page":"e42441","DOI":"10.1371\/journal.pone.0042441","article-title":"An in vivo C. elegans model system for screening EGFR-inhibiting anti-cancer drugs","volume":"7","author":"Bae","year":"2012","journal-title":"PLoS One"},{"key":"2025040317224549700_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12935-019-0880-4","article-title":"Harmine suppresses hyper-activated Ras\u2013MAPK pathway by selectively targeting oncogenic mutated Ras\/Raf in Caenorhabditis elegans","volume":"19","author":"Ji","year":"2019","journal-title":"Cancer Cell Int"},{"key":"2025040317224549700_bib27","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1073\/pnas.92.8.3333","article-title":"Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans","volume":"92","author":"Hara","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025040317224549700_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/genetics\/77.1.71","article-title":"The genetics of Caenorhabditis elegans","volume":"77","author":"Brenner","year":"1974","journal-title":"Genetics"},{"key":"2025040317224549700_bib29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ydbio.2005.03.002","article-title":"C. elegans PlexinA PLX-1 mediates a cell contact-dependent stop signal in vulval precursor cells","volume":"282","author":"Liu","year":"2005","journal-title":"Dev Biol"},{"key":"2025040317224549700_bib30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1289\/ehp.1409645","article-title":"Developmental effects of the ToxCastTM phase I and phase II chemicals in Caenorhabditis elegans and corresponding responses in zebrafish, rats, and rabbits","volume":"124","author":"Boyd","year":"2016","journal-title":"Environ Health Perspect"},{"key":"2025040317224549700_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/jat.3357","article-title":"The C. elegans model in toxicity testing","volume":"37","author":"Hunt","year":"2017","journal-title":"J Appl Toxicol"},{"key":"2025040317224549700_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screen"},{"key":"2025040317224549700_bib33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1091\/mbc.5.4.395","article-title":"The lin-15 locus encodes two negative regulators of Caenorhabditis elegans vulval development","volume":"5","author":"Huang","year":"1994","journal-title":"Mol Biol Cell"},{"key":"2025040317224549700_bib34","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1101\/gad.9.24.3149","article-title":"The Caenorhabditis elegans gene lin-1 encodes an ETS-domain protein and defines a branch of the vulval induction pathway","volume":"9","author":"Beitel","year":"1995","journal-title":"Genes Dev"},{"key":"2025040317224549700_bib35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/etc.5620200419","article-title":"Assessment of sublethal endpoints for toxicity testing with the nematode Caenorhabditis elegans","volume":"20","author":"Anderson","year":"2001","journal-title":"Environ Toxicol Chem"},{"key":"2025040317224549700_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10646-006-0108-y","article-title":"Endocrine disruption in nematodes: effects and mechanisms","volume":"16","author":"H\u00f6ss","year":"2007","journal-title":"Ecotoxicology"},{"key":"2025040317224549700_bib37","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/molecules22101551","article-title":"Current development status of MEK inhibitors","volume":"22","author":"Cheng","year":"2017","journal-title":"Molecules"},{"key":"2025040317224549700_bib38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjh.14285","article-title":"Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia","volume":"175","author":"Chen","year":"2016","journal-title":"Br J Haematol"},{"key":"2025040317224549700_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2017.00051","article-title":"Inhibition of H3K27me3 histone demethylase activity prevents the proliferative regeneration of zebrafish lateral line neuromasts","volume":"10","author":"Bao","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"2025040317224549700_bib40","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/1535-7163.MCT-19-0858","article-title":"Efficacy, tolerability, and pharmacokinetics of combined targeted MEK and dual mTORC1\/2 inhibition in a preclinical model of mucosal melanoma","volume":"19","author":"Wei","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2025040317224549700_bib41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J Med Chem"},{"key":"2025040317224549700_bib42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1101\/gad.9.6.742","article-title":"MEK-2, a Caenorhabditis elegans MAP kinase kinase, functions in Ras-mediated vulval induction and other developmental events","volume":"9","author":"Wu","year":"1995","journal-title":"Genes Dev"},{"key":"2025040317224549700_bib43","first-page":"1","article-title":"RTK\/Ras\/MAPK signaling","volume":"11","author":"Sundaram","year":"2006","journal-title":"WormBook"},{"key":"2025040317224549700_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4939-7219-7_3","article-title":"C. elegans vulva induction: an in vivo model to study epidermal growth factor receptor signaling and trafficking","volume":"1652","author":"Gauthier","year":"2017","journal-title":"Methods Mol Biol"},{"key":"2025040317224549700_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/toxsci\/kfn121","article-title":"Caenorhabditis elegans: an emerging model in biomedical and environmental toxicology","volume":"106","author":"Leung","year":"2008","journal-title":"Toxicol Sci"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0221\/3491502\/crc-24-0221.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/9\/2454\/3498470\/crc-24-0221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/9\/2454\/3498470\/crc-24-0221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:56:37Z","timestamp":1743728197000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/9\/2454\/748494\/A-Drug-Discovery-Pipeline-for-MAPK-ERK-Pathway"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0221","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.27052912","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052924","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052927.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052897","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052906","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728196","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052918","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052918.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052924.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052930","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728190","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052897.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052909","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728199","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728202","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052930.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052933.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052903","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728193","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052915","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052927","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052903.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052933","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052909.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052915.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052906.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27052912.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728205","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7454887","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7454887.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}